Logo
Paradigm Biopharmaceuticals

DevelopmentPipeline

Paradigm Biopharmaceuticals is focused on developing therapies that address areas of significant unmet medical need. Our development pipeline reflects a commitment to advancing treatments that may improve patient outcomes across a range of serious and chronic conditions, with a focus on diseases where better therapeutic options are urgently needed.

What do the stages mean?

Proof of conceptPhase 1Phase 2Phase 3Registration

ReachedNowNot yet

Proof of concept
Laboratory or animal work, before any testing in people.
Phase 1
A first study in people, looking at safety and dosing.
Phase 2
A study in people who have the condition.
Phase 3
A large controlled study, run to support a regulatory submission.
Registration
Assessment by a medicines regulator. No Paradigm programme is at this stage.
Active
Work is happening now.
Completed
The study has finished. What happens next is on the row.
Exploratory
Preclinical work, or a programme under review.

Showing all 8 programmes.

Osteoarthritis
Lysosomal storage diseases
Inflammatory arthritis
Respiratory
Cardiovascular
A rendered knee joint

Knee osteoarthritis

Active

Zilosul® (injectable PPS)

Proof of conceptPhase 3

PARA_OA_012 · NCT06917404

Trial start
29 May 2025
Participants
538 dosed, against a 466 target
Sites
65 across four countries
Enrolment
Completed 15 June 2026
Next milestone
Interim analysis, September 2026
Topline
Q1 2027
Designation
FDA Fast Track, April 2022
View programme

Zilosul® is an investigational product, not approved for sale or available for prescription. Stages shown are the most advanced study reached in each indication.

Osteoarthritis

Recognising the pressing need for new, safe, and effective treatments for the symptoms and underlying disease pathology of OA, Paradigm is developing PPS for OA under the trademark, Zilosul®.

Programmes
  • —Knee osteoarthritis, Phase 3
Click here to learn more
A rendered knee joint